<< Back to News

System Formulary Update
Oral Oncolytic Agents (Part II)
January 1, 1970

Situation

The oral oncolytic agents class review and formulary standardization (Part II) was approved by the System Pharmacy & Therapeutics Committee in May 2022.

Background

The following medications were reviewed: exemestane (Aromasin); imatinib (Gleevec); temozolomide (Temodar); venetoclax (Venclexta); ruxolitinib (Jakafi)

Assessment/Recommendation

Changes effective: Tuesday, June 28^th

System P&T voted to include the following products on the UNC Health Care System Drug Formulary:

• Exemestane (Aromasin) 25 mg tablets.
• Imatinib (Gleevec) 100 mg tablets. Orders must be signed by a Hematology/Oncology Attending Physician.
• Temozolomide (Temodar) 20 mg and 100 mg capsules. Orders must be signed by a Hematology/Oncology Attending Physician.
• Venetoclax (Venclexta) 100 mg tablets. Use is restricted to initiation in patients with acute myeloid leukemia (AML), and orders must be signed by a Hematology/Oncology Attending Physician.
• Ruxolitinib (Jakafi) 5 mg and 10 mg tablets. Orders must be signed by a Hematology/Oncology Attending Physician.

System P&T voted to exclude the following products on the UNC Health Care System Drug Formulary:

• Imatinib (Gleevec) 400 mg tablets.
• Temozolomide (Temodar) 5 mg, 140 mg, and 250 mg capsules.
• Venetoclax (Venclexta) 10 mg and 50 mg tablets.
• Ruxolitinib (Jakafi) 20 mg tablets.

Note: Stock of these formulary products may vary at individual entities